Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02578810
Other study ID # MUGraz2
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 2016
Est. completion date December 2025

Study information

Verified date November 2023
Source Suez Canal University
Contact Ashraf Dahaba, MD
Phone 00436509006761
Email ashraf.dahaba@medunigraz.at
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Pre-eclampsia, more than being proteinuric gestational hypertension alone, is a state of exaggerated systemic inflammation and remains a leading direct cause of maternal morbidity and mortality worldwide.1 Standardization of antenatal and postnatal assessment and surveillance of pre-eclampsia with protocols that recognize the systemic inflammatory model of preeclampsia have been associated with reduced maternal morbidity.


Description:

Background: Pre-eclampsia, more than being proteinuric gestational hypertension alone, is a state of exaggerated systemic inflammation and remains a leading direct cause of maternal morbidity and mortality worldwide.1 Standardization of antenatal and postnatal assessment and surveillance of pre-eclampsia with protocols that recognize the systemic inflammatory model of preeclampsia have been associated with reduced maternal morbidity.2 To quantitatively asses electroencephalography (EEG) mental involvement in Pre-eclampsia is still time consuming and not always readily available. PIERS was developed and internally validate as a pre-eclampsia outcome prediction model- (Preeclampsia Integrated Estimate of RiSk) model.3 The purpose of our study was to evaluate the discriminative power of the Bispectral Index (BIS), biomarkers sFIT (soluble FMS-like Tyrosine Kinase): PIGF (Placental Growth Factor) ratio,4 and adrenomedullin mortality risk stratifier,5 to classify the degree and progression of pre-eclampsia. Methods: In 24 patients with Eclampsia or pre-eclampsia investigators will use an artefact-free 20-min mean BIS value, as well as biomarkers sFIT (soluble FMS-like Tyrosine Kinase): PIGF (Placental Growth Factor) ratio and adrenomedullin mortality risk stratifier to classify the degree of pre-eclampsia correlated the PIERS Pre-eclampsia risk assessment PIERS percentage (http://piers.cfri.ca/PIERSCalculatorH.aspx) will be calculated from patients' clinical and laboratory findings documented in their charts, compared with 24 pregnant patients without Eclampsia or pre-eclampsia.


Recruitment information / eligibility

Status Recruiting
Enrollment 48
Est. completion date December 2025
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria 1. Pregnancy at any stage (3 trimesters) 2. Eclampsia (Frank eclampsia) will be the crux of the study 3. Pre-eclampsia that is suspected will end up with Frank Eclampsia Exclusion criteria: 1. Any neurological conditions that can alter the electroencephalography like epilepsy 2. Any medical conditions that can alter the electroencephalography like hypoglycemia

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Malaysia Medical Ethics Committee, University Malaya Medical Centre Kuala Lumpur

Sponsors (2)

Lead Sponsor Collaborator
Suez Canal University University of Malaya

Country where clinical trial is conducted

Malaysia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Decline in BIS our hypothesis is that a decline of Bispectral Index (BIS) assuming to be in the range of 15-60 will correlate to the with a high PIERS we can then quantify this BIS decline maybe in 4 Eclampsia grades we will record Bispectral Index (BIS) for a quite 20 min no tactile contact or noise that could raise the BIS inadvertently
See also
  Status Clinical Trial Phase
Completed NCT02911701 - Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features Phase 4
Recruiting NCT06377878 - The Preeclampsia Registry
Recruiting NCT02020174 - The Preeclampsia Registry
Completed NCT05121415 - Investigation of Genetic Disease Marker Associated With Spontaneous Haemorrhagic Stroke Complicating Severe Pre-eclampsia in Pregnancy
Recruiting NCT02920593 - A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy Phase 4
Completed NCT05143710 - The Clinical and Prognostic Features of PRES
Completed NCT03028194 - Postpartum Uterine Curettage in the Recovery From Preeclampsia/Eclampsia N/A
Recruiting NCT05678062 - Point-of-care Ultrasound Abnormalities in Eclampsia N/A
Unknown status NCT02256995 - uChek Pilot Study for Urinalysis in the Antenatal Care Setting N/A
Completed NCT01751945 - Improved Accessibility of EmONC Services for Maternal and Newborn Health: a Community Based Project N/A
Recruiting NCT06069102 - Optimal Blood Pressure Treatment Thresholds Postpartum Phase 4
Recruiting NCT06219109 - Pulmonary Edema Resolution in Severe Preeclampsia and Eclampsia
Recruiting NCT06281665 - Treatment With Aspirin After Preeclampsia: TAP Trial Phase 4
Completed NCT02765906 - Comparing Different Methods of Patient Education on Preeclampsia N/A
Completed NCT04160923 - Incidence and Neonatal Outcome of Eclamptic Parturient in Tertiary Hospital.
Recruiting NCT01856387 - The Effect of neutrophil-to Lymphocyte Ratio in Preeclampsia- Eclampsia N/A
Recruiting NCT03200743 - Catestatin and Hypertension in Pregnancy N/A
Not yet recruiting NCT04855513 - Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial N/A
Completed NCT00000534 - Calcium for Pre-Eclampsia Prevention (CPEP) Phase 3
Recruiting NCT05655936 - Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial N/A